{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:09:58Z","timestamp":1775095798274,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jchf.2024.03.021","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T18:41:16Z","timestamp":1720636876000},"page":"1803-1813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heart\u00a0Failure Drug Development Over\u00a0the\u00a0Eras"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-5015","authenticated-orcid":false,"given":"Vanessa","family":"Blumer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell A.","family":"Psotka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-4698","authenticated-orcid":false,"given":"Michael R.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charu","family":"Gandotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R.","family":"Saville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jchf.2024.03.021_bib1","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American\u00a0College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.021_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","article-title":"Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC Review Topic of the Week","volume":"79","author":"Fiuzat","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.021_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2019.12.011","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jchf.2022.09.012","article-title":"Functional and symptomatic clinical trial endpoints: the HFC-ARC Scientific Expert Panel","volume":"10","author":"Psotka","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2020.10.014","article-title":"Treatment of HF in an era of multiple therapies: statement from the HF Collaboratory","volume":"9","author":"Bhatt","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41569-022-00705-w","article-title":"The need for increased pragmatism in cardiovascular clinical trials","volume":"19","author":"Usman","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2024.03.021_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib12","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(22)01601-4","article-title":"The evolving landscape of pulmonary arterial hypertension clinical trials","volume":"400","author":"Weatherald","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.03.021_bib13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.cjca.2021.06.023","article-title":"Adaptive trials in cardiology: some considerations and examples","volume":"37","author":"Mandrola","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jchf.2024.03.021_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005879","article-title":"Impact of autonomic regulation therapy in patients with heart failure","volume":"12","author":"Konstam","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jchf.2019.04.004","article-title":"Bucindolol for the maintenance of sinus rhythm in a genotype-defined HF population: the GENETIC-AF trial","volume":"7","author":"Piccini","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The Platform Trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2024.03.021_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.jchf.2024.03.021_bib19","doi-asserted-by":"crossref","first-page":"P202","DOI":"10.1016\/j.cardfail.2023.10.209","article-title":"Variation of prespecified subgroups in large-scale HF outcome trials","volume":"30","author":"Dimond","year":"2024","journal-title":"J\u00a0Cardiac Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib20","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib21","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib22","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and\u00a0reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.021_bib24","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/ejhf.2675","article-title":"Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart\u00a0Failure Association of the European Society of Cardiology","volume":"24","author":"Bayes-Genis","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcin.2011.03.008","article-title":"The Academic Research Consortium governance charter","volume":"4","author":"Krucoff","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jchf.2024.03.021_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jchf.2019.07.001","article-title":"Design of a \"lean\" case report form for heart failure therapeutic development","volume":"7","author":"Psotka","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.jchf.2024.03.021_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jchf.2024.02.016","article-title":"Training the next generation of data monitoring committee members: an initiative of the heart failure collaboratory","volume":"12","author":"Fleming","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jchf.2024.03.021_bib34","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/europace\/euac052","article-title":"Wearables, telemedicine, and artificial intelligence in arrhythmias and heart failure: Proceedings of the European Society of Cardiology Cardiovascular Round Table","volume":"24","author":"Leclercq","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.jchf.2024.03.021_bib35","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.jacc.2018.03.521","article-title":"Artificial intelligence in cardiology","volume":"71","author":"Johnson","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.03.021_bib36","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.2859","article-title":"A\u00a0machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial","volume":"25","author":"Kobayashi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchf.2021.08.008","article-title":"Remote speech analysis in the evaluation of hospitalized patients with acute decompensated heart failure","volume":"10","author":"Amir","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2024.03.021_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","article-title":"Artificial intelligence for clinical trial design","volume":"40","author":"Harrer","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jchf.2024.03.021_bib39","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/pharmaceutics15071916","article-title":"Artificial intelligence in pharmaceutical technology and drug delivery design","volume":"15","author":"Vora","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jchf.2024.03.021_bib40","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2589-7500(23)00065-1","article-title":"Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study","volume":"5","author":"Banerjee","year":"2023","journal-title":"Lancet Digital Health"},{"key":"10.1016\/j.jchf.2024.03.021_bib42","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/CIRCULATIONAHA.119.041728","article-title":"Overcoming lack of diversity in cardiovascular clinical trials","volume":"140","author":"Ortega","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.03.021_bib43","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A\u00a0trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Eichhorn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2024.03.021_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jchf.2021.03.005","article-title":"Promoting diversity in clinical trial leadership: a call to action","volume":"9","author":"Lindenfeld","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924004165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T19:25:02Z","timestamp":1730748302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924004165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2213177924004165"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.03.021","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart\u00a0Failure Drug Development Over\u00a0the\u00a0Eras","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}